Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP3 | P42574 | 4/20 | 0.54 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.41 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.38 |
| ▸ | MDM4 | O15151 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29415585 | 0.89 | CASP3 (0.53) | CASP3EPHX2KMT2APIN1 | |
| SCHEMBL29352081 | 0.89 | CASP3 (0.53) | CASP3EPHX2KMT2APIN1 | |
| SCHEMBL21731443 | 0.89 | CASP3 (0.53) | CASP3EPHX2KMT2APIN1 | |
| SCHEMBL16285132 | 0.89 | CASP3 (0.53) | CASP3EPHX2KMT2APIN1 | |
| SCHEMBL15482107 | 0.89 | CASP3 (0.53) | CASP3EPHX2KMT2APIN1 | |
| SCHEMBL22283287 | 0.89 | CASP3 (0.53) | CASP3EPHX2KMT2APIN1 | |
| SCHEMBL16646584 | 0.89 | CASP3 (0.52) | CASP3EPHX2KMT2APIN1 | |
| SCHEMBL29677937 | 0.89 | CASP3 (0.52) | CASP3EPHX2KMT2APIN1 | |
| SCHEMBL16634928 | 0.89 | CASP3 (0.53) | CASP3EPHX2KMT2APIN1MDM2 | |
| SCHEMBL20880298 | 0.87 | CASP3 (0.51) | CASP3EPHX2KMT2APIN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024129614-A1 | SOMATOSTATIN SUBTYPE-2 RECEPTOR (SST2R) TARGETED THERAPEUTICS AND USES THEREOF | Crinetics Pharmaceuticals, Inc. (US) | 2024-06-20 | — | — | WO | disclosed |
| WO-2023096904-A2 | C-16 MODIFIED TRIOXACARCINS, ANTIBODY DRUG CONJUGATES, AND USES THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2023-06-01 | — | — | WO | disclosed |
| US-20190209704-A1 | NOVEL ANTIBODY-DRUG CONJUGATES AND RELATED COMPOUNDS, COMPOSITIONS AND METHODS OF USE | SENSEI BIOTHERAPEUTICS, INC. | 2019-07-11 | — | — | US | disclosed |
| EP-3209334-A2 | NOVEL ANTIBODY-DRUG CONJUGATES AND RELATED COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | Igenica Biotherapeutics, Inc. (US) | 2017-08-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190209704-A1 | NOVEL ANTIBODY-DRUG CONJUGATES AND RELATED COMPOUNDS, COMPOSITIONS AND METHODS OF USE | CYTH3, CD47, FCGRT | CASP3 572/4885EPHX2 741/4885KMT2A 2145/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.